Ó£ÌÒÊÓƵapp

This prespecified analysis of the POST-PCI randomized clinical trial analyzes clinical outcomes in patients with vs without acute coronary syndrome (ACS) who have undergone high-risk percutaneous coronary intervention (PCI) according to a follow-up strategy of routine surveillance stress testing vs standard care.

This randomized clinical trial investigates the effectiveness and safety of a nonphysician-led, multifaceted, intensive blood pressure intervention in younger and older individuals with hypertension.

This case-control study investigates the ability of a large-scale proteomics panel from first-trimester blood samples to predict the development of hypertensive disorders of pregnancy.

This randomized clinical trial evaluates the safety and efficacy of lerodalcibep vs placebo in reduction of low-density lipoprotein cholesterol in patients with or at risk of cardiovascular disease.

This secondary analysis of the ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness) randomized clinical trial investigates if there are sex-specific differences in the safety and effectiveness of 2 aspirin doses for the secondary prevention of atherosclerotic cardiovascular disease (CVD).

This post hoc analysis of a randomized clinical trial investigates if patients 80 years and older with atrial fibrillation benefit from lower-dose anticoagulants even in the absence of prespecified dose-reduction criteria.

This study investigates the impact of lipoprotein(a) levels on long-term coronary artery plaque progression, high-risk plaque, and pericoronary adipose tissue inflammation.

This meta-analysis evaluates lipoprotein(a) concentrations and hemodynamic progression in patients with aortic stenosis.

This randomized clinical trial investigates the effect of dapagliflozin on right ventricular performance and vascular load during exertion in heart failure with preserved ejection fraction (HFpEF).

This analysis of a randomized clinical trial examines the clinical event data to determine which source of data (eg, electronic health records, claims, participant reports) made the greatest relative contribution to the primary end point rates.